Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSURE: Secukinumab Extension in Uveitis
NCT01103024Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2010
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in noninfectious uveitis (NIU) (4 arms), sponsored by Novartis. Primary endpoint: Rate of recurrence at 52 weeks. Planned start Dec 2010; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT01103024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103024.